Agile Therapeutics, Inc, a women's healthcare company, focuses on the development and commercialization of prescription contraceptive products for women. Its lead product candidate is Twirla, also known as AG200-15, a once-weekly prescription contraceptive patch, which completed Phase III clinical trials. The company is also developing a pipeline of other transdermal contraceptive products, including AG200-ER, a regimen that allows a woman to extend the length of her cycle; AG200-SP, which is a regimen designed to provide shorter lighter periods; AG200-ER (SmP), a regimen to allow a woman to extend the length of her cycle, as well as experience shorter and lighter periods; and AG890, a progestin-only contraceptive patch intended for use by women who are unable or unwilling to take estrogen.
Read More…
Industry, Sector and Symbol
Industry N/A
Sub-IndustryN/A
SectorN/A
WebN/A
PhoneN/A
Debt
Price-To-Earnings
Sales & Book Value
Annual SalesN/A
Profitability
Miscellaneous
Employees13
Next Earnings Date3/10/2020 (Estimated)
OptionableOptionable
Agile Therapeutics (NASDAQ:AGRX) Frequently Asked Questions
What is Agile Therapeutics' stock symbol?
Agile Therapeutics trades on the NASDAQ under the ticker symbol "AGRX."
How were Agile Therapeutics' earnings last quarter?
Agile Therapeutics Inc (NASDAQ:AGRX) issued its quarterly earnings data on Monday, October, 28th. The specialty pharmaceutical company reported ($0.08) EPS for the quarter, missing analysts' consensus estimates of ($0.08) by $0.00. View Agile Therapeutics' Earnings History.
When is Agile Therapeutics' next earnings date?
What price target have analysts set for AGRX?
5 Wall Street analysts have issued 1-year price targets for Agile Therapeutics' shares. Their forecasts range from $3.00 to $5.00. On average, they expect Agile Therapeutics' stock price to reach $4.25 in the next twelve months. This suggests a possible upside of 4.4% from the stock's current price. View Analyst Price Targets for Agile Therapeutics.
What is the consensus analysts' recommendation for Agile Therapeutics?
5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Agile Therapeutics in the last year. There are currently 5 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Agile Therapeutics.
What are Wall Street analysts saying about Agile Therapeutics stock?
Here are some recent quotes from research analysts about Agile Therapeutics stock:
- 1. According to Zacks Investment Research, "Agile Therapeutics, Inc. is a women's health specialty pharmaceutical company. It is focused on the development and commercialization of new prescription contraceptive products. The Company's lead product candidate is Twirla (TM), also known as AG200-15, a once-weekly prescription contraceptive patch currently in Phase 3 clinical development. Agile Therapeutics, Inc. is headquartered in Princeton, New Jersey. " (2/5/2020)
- 2. Maxim Group analysts commented, "Agile Therapeutics announced that the NDA for Twirla (low-dose contraceptive patch) has been resubmitted to the FDA. FDA has 30 days to accept; review period expected to be 6 months." (5/17/2019)
Has Agile Therapeutics been receiving favorable news coverage?
Headlines about AGRX stock have trended somewhat positive this week, according to InfoTrie Sentiment. The research firm scores the sentiment of news coverage by reviewing more than six thousand blog and news sources in real-time. The firm ranks coverage of companies on a scale of negative five to positive five, with scores closest to five being the most favorable. Agile Therapeutics earned a news impact score of 2.0 on InfoTrie's scale. They also gave media headlines about the specialty pharmaceutical company a news buzz of 0.0 out of 10, indicating that recent news coverage is extremely unlikely to have an effect on the company's share price in the immediate future. View News Stories for Agile Therapeutics.
What other stocks do shareholders of Agile Therapeutics own?
Who are Agile Therapeutics' key executives?
Agile Therapeutics' management team includes the folowing people:
- Mr. Alfred F. Altomari, Chairman & CEO (Age 60)
- Mr. Scott M. Coiante, CFO & Sr. VP (Age 52)
- Dr. Elizabeth Ijeoma Onyemelukwe Garner, Sr. VP & Chief Medical Officer (Age 51)
- Mr. Geoffrey P. Gilmore, Gen. Counsel (Age 53)
- Mr. Robert G. Conway, Sr. VP of Enterprise Planning & Information Management (Age 62)
Who are Agile Therapeutics' major shareholders?
Agile Therapeutics' stock is owned by many different of retail and institutional investors. Top institutional investors include Perceptive Advisors LLC (20.10%), Renaissance Technologies LLC (5.51%), Schonfeld Strategic Advisors LLC (1.50%), EAM Investors LLC (0.55%), Credit Suisse AG (0.28%) and Oxford Asset Management LLP (0.11%). Company insiders that own Agile Therapeutics stock include Abhijeet J Lele, Alfred Altomari, Life Sciences Maste Perceptive and Perceptive Advisors Llc. View Institutional Ownership Trends for Agile Therapeutics.
Which institutional investors are buying Agile Therapeutics stock?
AGRX stock was purchased by a variety of institutional investors in the last quarter, including Perceptive Advisors LLC, Schonfeld Strategic Advisors LLC, Renaissance Technologies LLC, EAM Investors LLC, Credit Suisse AG, Oxford Asset Management LLP, Bank of New York Mellon Corp and Pinnacle Wealth Management Advisory Group LLC. Company insiders that have bought Agile Therapeutics stock in the last two years include Abhijeet J Lele, Alfred Altomari and Perceptive Advisors Llc. View Insider Buying and Selling for Agile Therapeutics.
How do I buy shares of Agile Therapeutics?
Shares of AGRX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.
What is Agile Therapeutics' stock price today?
One share of AGRX stock can currently be purchased for approximately $4.07.
MarketBeat Community Rating for Agile Therapeutics (NASDAQ AGRX)
MarketBeat's community ratings are surveys of what our community members think about Agile Therapeutics and other stocks. Vote "Outperform" if you believe AGRX will outperform the S&P 500 over the long term. Vote "Underperform" if you believe AGRX will underperform the S&P 500 over the long term. You may vote once every thirty days.
